Pfizer (PFE) Receiving Somewhat Favorable Press Coverage, Study Finds
News stories about Pfizer (NYSE:PFE) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pfizer earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.6123957104938 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- Pfizer’s (PFE) Besponsa Gets FDA Nod with a Boxed Warning – Nasdaq (nasdaq.com)
- Options Indicator Swings Bearish For Pfizer Inc. (PFE) – StockNews.com (blog) (stocknews.com)
- Notable Two Hundred Day Moving Average Cross – PFE – Nasdaq (nasdaq.com)
- [$$] Healthy Dividends (finance.yahoo.com)
- Pfizer, Inc. (PFE) Given “Hold” Rating at Jefferies Group LLC (americanbankingnews.com)
Shares of Pfizer (PFE) traded down 0.85% during trading on Friday, reaching $32.67. 15,490,145 shares of the company were exchanged. Pfizer has a one year low of $29.83 and a one year high of $35.38. The company has a market capitalization of $194.30 billion, a PE ratio of 23.90 and a beta of 1.00. The firm’s 50 day moving average price is $33.30 and its 200 day moving average price is $33.38.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The firm had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same period in the previous year, the firm earned $0.64 earnings per share. The business’s revenue was down 1.9% compared to the same quarter last year. Equities research analysts forecast that Pfizer will post $2.56 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be given a dividend of $0.32 per share. The ex-dividend date of this dividend is Wednesday, August 2nd. This represents a $1.28 annualized dividend and a dividend yield of 3.92%. Pfizer’s dividend payout ratio is presently 94.12%.
A number of equities research analysts recently issued reports on the stock. Jefferies Group LLC reiterated a “hold” rating and set a $35.00 target price on shares of Pfizer in a research report on Friday. Berenberg Bank reiterated a “hold” rating and set a $36.00 target price (down previously from $39.00) on shares of Pfizer in a research report on Tuesday. Cowen and Company set a $43.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, August 14th. BidaskClub raised shares of Pfizer from a “strong sell” rating to a “sell” rating in a report on Saturday, August 5th. Finally, BMO Capital Markets raised shares of Pfizer from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $33.00 to $37.00 in a report on Wednesday, August 2nd. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have given a buy rating to the company’s stock. Pfizer presently has an average rating of “Hold” and an average price target of $37.61.
In other Pfizer news, CEO Ian C. Read sold 96,950 shares of the business’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $34.00, for a total value of $3,296,300.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the sale, the insider now directly owns 151,474 shares in the company, valued at $5,074,379. The disclosure for this sale can be found here. Insiders own 0.06% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.